person · Reporting owner

Fust Matthew K

Disclosed activity across 7 companies

Tapewire entity: 17933
SEC CIK: 0001397266

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Atara Biotherapeutics, Inc.ATRA · Entity 6828	Director	June 09, 2026	June 11, 2026
Electra Therapeutics, Inc.ETRA · Entity 9265	Director	September 18, 2026	September 18, 2026
MACROGENICS INCMGNX · Entity 6104	Director	May 16, 2019	May 20, 2019
Neumora Therapeutics, Inc.NMRA · Entity 6115	Director	May 27, 2026	May 29, 2026
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	Director	May 14, 2026	May 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atara Biotherapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,188	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Grant · Acquired 12,000 · Balance 30,188 F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Electra Therapeutics, Inc.

Report date September 18, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2033-11-16	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-18 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 · Expires 2036-02-12	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-18 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-09-16	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.

MACROGENICS INC

Report date May 16, 2019 · Filed May 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2029-05-16	Direct	10,000	Reported balance After 2019-05-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Neumora Therapeutics, Inc.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26	Direct	80,000	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

Ultragenyx Pharmaceutical Inc.

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,696	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 33,696 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14	Direct	14,058	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Crinetics Pharmaceuticals, Inc.

Report date September 01, 2026 · Filed September 01, 2026

Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2026-09-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-01 · Disposition to issuer · Disposed 22,836 · Balance 5,925 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 5,925 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2028-03-16	Direct	Reported balance After 2026-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-01 · Disposition to issuer · Disposed 2,092 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.32 · Expires 2033-06-15	Direct	Reported balance After 2026-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-01 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.71 · Expires 2034-06-07	Direct	Reported balance After 2026-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-01 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.33 · Expires 2035-06-11	Direct	Reported balance After 2026-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-01 · Disposition to issuer · Disposed 10,350 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2036-06-18	Direct	Reported balance After 2026-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-01 · Disposition to issuer · Disposed 9,730 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").

F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.

F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Dermira, Inc.

Report date February 20, 2020 · Filed February 25, 2020

Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-02-20 transaction · row 1 1 source row Row 1 · 2020-02-20 · Disposition to issuer · Disposed 5,051 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-05	Direct	Reported balance After 2020-02-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-20 · Disposition to issuer · Disposed 14,224 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10	Direct	Reported balance After 2020-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20	Direct	Reported balance After 2020-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12	Direct	Reported balance After 2020-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12	Direct	Reported balance After 2020-02-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03	Direct	Reported balance After 2020-02-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 07, 2024 Filed Jun 11, 2024 20:19 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $44.71	$0.00	Disclosure SEC source: 0000950170-24-071924 · ownership.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-07 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 07, 2024 Filed Jun 11, 2024 20:19 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock	3,400	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071924 · ownership.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,936 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
March 31, 2024 Filed Apr 2, 2024 22:13 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	150,000	$0.00	$0.00	Disclosure SEC source: 0000905148-24-001060 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,000 F1 · shares: These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $18.29	$0.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · derivative · entry 12 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $20.23	$0.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · derivative · entry 11 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2031-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $23.23	$0.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · derivative · entry 10 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $23.24	$0.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · derivative · entry 9 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	17,500	$45.50	$796,250.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 8 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,536 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	17,500	$18.29	$320,075.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 7 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	17,500	$43.58	$762,650.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 6 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,536 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	17,500	$20.23	$354,025.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 5 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	12,500	$43.57	$544,625.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,536 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	12,500	$23.23	$290,375.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	12,500	$43.57	$544,625.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,536 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	12,500	$23.24	$290,500.00	Disclosure SEC source: 0001209191-24-005060 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 07, 2024 Filed Mar 11, 2024 16:54 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	7,500	$50.88	$381,600.00	Disclosure SEC source: 0000950170-24-029040 · ownership.xml · nonDerivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,860 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 07, 2024 Filed Mar 11, 2024 16:54 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	2,145	$50.85	$109,073.25	Disclosure SEC source: 0000950170-24-029040 · ownership.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,360 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 07, 2024 Filed Mar 11, 2024 16:54 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	2,550	$50.89	$129,769.50	Disclosure SEC source: 0000950170-24-029040 · ownership.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,505 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 14, 2023 Filed Sep 18, 2023 21:51 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	27,802	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001610717-23-000282 · form4.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,802 Underlying: Common Stock · 27,802 shares Expires 2033-09-13 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest and become exercisable on the date of the 2024 Annual Meeting, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 16, 2023 Filed Jun 21, 2023 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $20.32	$0.00	Disclosure SEC source: 0001209191-23-038819 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-15 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 16, 2023 Filed Jun 21, 2023 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-038819 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,536 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 18:32 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	7,110	$0.00 Strike: $51.82	$0.00	Disclosure SEC source: 0001209191-23-035691 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires 2033-06-07 F3 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document
June 07, 2023 Filed Jun 9, 2023 18:32 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Disposition to issuerCommon Stock	3,300	$51.82	$171,006.00	Disclosure SEC source: 0001209191-23-035691 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,055 F2 · shares: Shares were acquired upon the vesting of a previously reported RSU and were disposed of to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person. Read SEC document
June 07, 2023 Filed Jun 9, 2023 18:32 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	3,860	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035691 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,355 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document
May 31, 2023 Filed Jun 2, 2023 23:09 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	79,500	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0001140361-23-028152 · form4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2033-05-30 F2 · derivative.exercise_date: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
May 31, 2023 Filed Jun 2, 2023 23:09 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	57,000	$0.00	$0.00	Disclosure SEC source: 0001140361-23-028152 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 F1 · shares: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	5,700	$0.00 Strike: $1.45	$0.00	Disclosure SEC source: 0001209191-22-042245 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,700 shares Expires 2027-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017. Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	5,700	$20.96	$119,454.90	Disclosure SEC source: 0001209191-22-042245 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F2 · kind: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017. Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	5,700	$1.45	$8,265.00	Disclosure SEC source: 0001209191-22-042245 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document
June 24, 2022 Filed Jun 28, 2022 17:52 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	6,245	$0.00 Strike: $60.57	$0.00	Disclosure SEC source: 0001209191-22-039566 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document
June 24, 2022 Filed Jun 28, 2022 17:52 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	3,300	$0.00	$0.00	Disclosure SEC source: 0001209191-22-039566 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,495 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:48 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	31,500	$0.00 Strike: $7.35	$0.00	Disclosure SEC source: 0001140361-22-024164 · form4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:48 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	20,500	$0.00	$0.00	Disclosure SEC source: 0001140361-22-024164 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 17, 2022 Filed Jun 21, 2022 20:46 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $18.29	$0.00	Disclosure SEC source: 0001209191-22-038438 · doc4.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
March 04, 2022 Filed Mar 8, 2022 17:25 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $40.37	$0.00	Disclosure SEC source: 0001209191-22-016930 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in full on on June 18, 2015. Read SEC document
March 04, 2022 Filed Mar 8, 2022 17:25 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionCommon Stock	7,500	$40.37	$302,775.00	Disclosure SEC source: 0001209191-22-016930 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
November 04, 2021 Filed Nov 5, 2021 20:28 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	SaleCommon Stock	13,354	$19.50	$260,403.00	Disclosure SEC source: 0001567619-21-019403 · doc1.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 14, 2021. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:55 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	8,954	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-21-062728 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,092 Underlying: Common stock · 8,954 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:55 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	8,954	$25.50	$228,327.00	Disclosure SEC source: 0001209191-21-062728 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:55 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	8,954	$1.91	$17,102.14	Disclosure SEC source: 0001209191-21-062728 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document
September 08, 2021 Filed Sep 9, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	6,046	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-21-055314 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,046 Underlying: Common stock · 6,046 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
September 08, 2021 Filed Sep 9, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	6,046	$25.50	$154,173.00	Disclosure SEC source: 0001209191-21-055314 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
September 08, 2021 Filed Sep 9, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	6,046	$1.91	$11,547.86	Disclosure SEC source: 0001209191-21-055314 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document
July 26, 2021 Filed Jul 28, 2021 00:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	5,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-21-048375 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,092 Underlying: Common stock · 5,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
July 26, 2021 Filed Jul 28, 2021 00:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	5,000	$19.59	$97,950.00	Disclosure SEC source: 0001209191-21-048375 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.59. The range of sales prices on the transaction date was $19.53 to $20.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
July 26, 2021 Filed Jul 28, 2021 00:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	5,000	$1.91	$9,550.00	Disclosure SEC source: 0001209191-21-048375 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	5,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-21-047402 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,092 Underlying: Common stock · 5,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	5,000	$19.50	$97,500.00	Disclosure SEC source: 0001209191-21-047402 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.50. The range of sales prices on the transaction date was $19.50 to $19.52 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	5,000	$1.91	$9,550.00	Disclosure SEC source: 0001209191-21-047402 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document
July 12, 2021 Filed Jul 13, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	5,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-21-046554 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,092 Underlying: Common stock · 5,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.